10-Q

United States

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended March 31, 2017

Commission File Number 0-20791

AMARILLO BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

TEXAS	75-1974352
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification No.)
4134 Business Park Drive, Amarillo, Texas 79110
(Address of principal executive offices) (Zip Code)
(806) 376-1741
(Issuer's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. [√ ] Yes   [ ] No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer [ ]	Accelerated filer [ ]
Non-accelerated filer [ ] (do not check if smaller reporting company)	Smaller reporting company [√]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act)[ ] Yes   [√] No

As of May 12, 2017, there were 22,350,935 shares of the issuer's common stock outstanding.

1

AMARILLO BIOSCIENCES, INC.

INDEX

		PAGE NO.
PART I:	FINANCIAL INFORMATION
ITEM 1.	Financial Statements
	Balance Sheets– March 31, 2017 and December 31, 2016 (unaudited)	3
	Statements of Operations – Three Months Ended March 31, 2017 and 2016 (unaudited)	4
	Condensed Statements of Cash Flows – Three Months Ended March 31, 2017 and 2016 (unaudited)	5
	Notes to Financial Statements (unaudited)	6
ITEM 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	9
ITEM 3.	Quantitative and Qualitative Disclosures About Market Risk.	11
ITEM 4.	Controls and Procedures	12
PART II:	OTHER INFORMATION
ITEM 1.	Legal Proceedings	13
ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	13
ITEM 3.	Defaults Upon Senior Securities	13
ITEM 4.	Mine Safety Disclosures	13
ITEM 5.	Other Information	13
ITEM 6.	Exhibits……………………………………………………………	13
Signatures		14

2

PART I - FINANCIAL INFORMATION

ITEM 1. Financial Statements

Amarillo Biosciences, Inc.

Balance Sheets

(Unaudited)

	March 31, 2017			December 31, 2016
Assets
Current assets:
Cash and cash equivalents	$	52,971		$	134,125
Inventory		-			14,700
Advance to related party		37,835			37,835
Prepaid expense and other current assets		61,463			75,739
Total current assets		152,269			262,399
Patents, net		155,962			156,063
Property and equipment, net		39,910			44,214
Total assets	$	348,141		$	462,676
Liabilities and Stockholders' Deficit
Current liabilities:
Accounts payable and accrued expenses	$	142,918		$	165,502
Accrued interest - related parties		7,154			3,259
Advance from related party		187,500			187,500
Customer deposits – related parties		124,833			124,833
Convertible note payable – related party		791,481			791,481
Total current liabilities		1,253,886			1,272,575
Total liabilities		1,253,886			1,272,575
Commitments and contingencies
Stockholders' deficit
Preferred stock, $0.01 par value:
Authorized shares - 10,000,000,
Issued and outstanding shares – 0 at March 31, 2017 and December 31, 2016		-			-
Common stock, $0.01 par value:
Authorized shares - 100,000,000,
Issued and outstanding shares – 22,350,935 and 21,916,143 at March 31, 2017 and December 31, 2016, respectively		223,509			219,161
Additional paid-in capital		326,318			237,540
Accumulated deficit		(1,455,572	)		(1,266,600	)
Total stockholders' deficit		(905,745	)		(809,899	)
Total liabilities and stockholders' deficit	$	348,141		$	462,676

See accompanying notes to financial statements.

3

Amarillo Biosciences, Inc.

Statements of Operations

(Unaudited)

	Three Months Ended March 31,
	2017			2016
Revenues:
Product sales	$	-		$	-
Total revenues		-			-
Cost of revenues:
Product costs		-			-
Total cost of revenues		-			-
Gross margin		-			-
Operating expenses:
Selling, general and administrative expenses		185,013			121,279
Total operating expenses		185,013			121,279
Operating loss		(185,013	)		(121,279	)
Other income (expense):
Interest expense		(3,959	)		(362	)
Net loss	$	(188,972	)	$	(121,641	)
Basic and diluted net loss per average share available to common shareholders	$	(0.01	)	$	(0.01	)
Weighted average common shares outstanding – basic and diluted		22,277,261			20,144,810

See accompanying notes to financial statements.

4

Amarillo Biosciences, Inc.

Condensed Statements of Cash Flows

(Unaudited)

	Three months ended March 31,
	2017			2016
Net cash provided by (used in) operating activities:	$	(126,512	)	$	1,663
Cash flows from investing activities:
Investment in patents		(5,267	)		(8,617	)
Net cash used in investing activities		(5,267	)		(8,617	)
Cash flows from financing activities:
Proceeds from private placement offering		50,625			250,000
Net cash provided by financing activities		50,625			250,000
Net change in cash		(81,154	)		243,046
Cash and cash equivalents at beginning of period		134,125			21,138
Cash and cash equivalents at end of period	$	52,971		$	264,184
Supplemental disclosure of cash flow information:
Cash paid for interest	$	-		$	-
Cash paid for income taxes	$	-		$	-
Noncash transactions:
Conversion of accounts payable – related party to convertible note payable – related party	$	-		$	144,426

See accompanying notes to financial statements.

5

Amarillo Biosciences, Inc.

Notes to Financial Statements

(Unaudited)

1. Organization and Business.  Amarillo Biosciences, Inc. (the "Company" or "ABI"), a Texas corporation formed in 1984, is engaged in developing biologics for the treatment of human and animal diseases.  The Company's current focus is research aimed at the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon alpha that is administered in a proprietary low dose oral form.  In addition to the above core technology, which is included in the Pharmaceutical Division, ABI is exploring the possibility of instituting new revenue streams with a Medical Division and a Consumer Products Division.

The Medical Division is preparing to deploy diabetic treatment centers in Taiwan beginning sometime in the third quarter of 2017. These centers will provide a therapy (Artificial Pancreas Treatment, or "APT") for the management of Type 1 and Type 2 diabetes along with the reversal of the complications that historically accompany this disease and plague patients. The Consumer Product Division is presently working on a delivery system for nutraceuticals and food supplements such as Vitamin C, negotiations to import and distribute to the Asian markets a natural resource product which can be modified for human, animal, or agricultural applications, and enter the alternative medicine market through domestic and international distribution of natural Kentucky Wild Ginseng and other medicinal herbs.

2. Basis of presentation. The accompanying financial statements, which should be read in conjunction with the financial statements and footnotes included in the Company's Form 10-K for the year ended December 31, 2016, filed with the Securities and Exchange Commission, are unaudited, but have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been included.  Operating results for the three months ended March 31, 2017 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2017.

3. Financial Condition.  These financial statements have been prepared in accordance with United States generally accepted accounting principles, on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has not yet achieved operating income, and its operations are funded primarily from debt and equity financings. However, losses are anticipated in the ongoing development of its business and there can be no assurance that the Company will be able to achieve or maintain profitability.

The continuing operations of the Company and the recoverability of the carrying value of assets is dependent upon the ability of the Company to obtain necessary financing to fund its working capital requirements, and upon future profitable operations. The accompanying financial statements do not include any adjustments relative to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result from the outcome of this uncertainty.

6

There can be no assurance that capital will be available as necessary to meet the Company's working capital requirements or, if the capital is available, that it will be on terms acceptable to the Company. The issuances of additional equity securities by the Company may result in dilution in the equity interests of its current stockholders. Obtaining commercial loans, assuming those loans would be available, will increase the Company's liabilities and future cash commitments. If the Company is unable to obtain financing in the amounts and on terms deemed acceptable, the business and future success may be adversely affected and the Company may cease operations. These factors raise substantial doubt regarding our ability to continue as a going concern.

4. Common Stock.  The shareholders have authorized 100,000,000 shares of voting common shares for issuance.  On March 31, 2017, a total of 26,661,574 shares of common stock were either issued (22,080,935) or reserved for issuance to an investor (270,000) or conversion of convertible debt to stock (4,310,639).

On March 10, 2016, the Board of Directors approved the Company to enter into private placements for the sale of up to 5,000,000 shares of the Company's common stock (Private Placement 2016-2) at a price of $.1875 per share (aggregate offering amount of $937,500).

On September 30, 2016, the Board of Directors approved the Company to amend the previously authorized Private Placement 2016-2 offer, sale, and issuance of unregistered securities.  The Private Placement 2016-2 was amended to offer up to 10,000,000 shares of the Company's common stock at a price of $.1875 per share for an aggregate offering amount of $1,875,000.  The offering is to be completed within one (1) year of the date of approval.  During the first quarter of 2017, the Company sold 270,000 shares of common stock at $.1875 per share for proceeds of $50,625.

On January 3, 2017, Stephen T. Chen, CEO, and Bernard Cohen, CFO/VP, received 145,405 shares of common stock and 19,387 shares of common stock, respectively, as payment of a 2016 stock bonus totaling $42,500.  The stock was issued at a price of $.2579 per share pursuant to the Board of Directors resolution of December 20, 2016.

No stock has been sold subsequent to the balance sheet date of March 31, 2017 and through the issue date of this report.

5. Convertible Notes Payable – Related Party.  During the fiscal year ended December 31, 2016, a payable in the amount of $144,426 to Dr. Stephen T. Chen, Chairman, CEO and President of the Company, was exchanged for a convertible promissory note.  The note was executed on January 11, 2016, is payable on demand, and is unsecured.  The interest rate is .75%, the Annual Federal Rate (AFR), the rate in effect when the note was made.  The Payee, Dr. Chen, may convert all or some part of the note to the Maker's (ABI's) common voting stock at a conversion price of $.168 per share.

On March 18, 2016, Dr. Chen purchased a Convertible Promissory Note in the amount of $262,500 through the Company's Private Placement Convertible Note Security Offering entitled Private Placement 2016-1 (previously approved by the ABI Board of Directors on March 10, 2016).  The note is payable on demand, unsecured, carries interest at the Short Term Annual Federal Rate (AFR) of .65% per annum, and is convertible into ABI common stock at a price of $.1875 per share.

7

On June 30, 2016, a Convertible Promissory Note in the amount of $384,555 was issued to Dr. Chen in exchange for the aggregated amounts of two existing Notes Payable – Related Party.  The Convertible Note is due on demand, is unsecured, bears interest at the Short-Term Applicable Federal Rate of .64% per annum, and is convertible into ABI common stock at a stock price of $.1875 per share.

	March 31, 2017		December 31, 2016
Convertible Note payable – related party	$	144,426	$	144,426
Convertible Note payable – related party		262,500		262,500
Convertible Note payable – related party		384,555		384,555
Convertible Notes payable – related party	$	791,481	$	791,481

6. Related Party Transactions. On May 23, 2016, Amarillo Biosciences, Inc. ("ABI"), the Principal, entered into an Agency and Service Agreement with ACTS Global Healthcare, Inc. ("ACTS Global"), a Taiwan Corporation, the Agent. To date, ABI has advanced to ACTS Global "Principal Funds" in the amount of NTD $3,000,681 ($91,968 USD), to be utilized and /or expended by ACTS Global solely as instructed by ABI.  Additional advances may be made by ABI to ACTS Global.  ACTS Global was also engaged by ABI to perform such other business services as may be requested by ABI in the agreed geographic area of Taiwan and the People's Republic of China.  That Agency Agreement is still in force.  For their services, ACTS Global, is be paid by ABI, one percent (1%) of the Principal's services expended by the Agent at the Principal's direction. Any other services rendered by the Agent will be paid for by the Principal based on comparable and/or reasonable values of the service rendered.  As of March 31, 2017, ACTS Global has a balance of $37,835 to be utilized for the benefit of the Company, which is included on the Company's Balance Sheet in Advance to related party.

In April 2016, the Company received proceeds of $187,500 from an investor related to Amarillo Biosciences (Hong Kong) Ltd. in exchange for the potential issuance of 1,000,000 shares of common stock (Private Placement 2016-2).  As of March 31, 2017, the shares have not been issued and the amount received is included in Advances from related party.  As of the filing date, the stock subscription has not been executed.

On December 20, 2016, effective January 1, 2017, the Board of Directors approved a resolution whereby Dr. Chen's annual compensation was changed to $90,000 cash per annum and $75,000 per annum payable in the Company's unregistered, voting common stock.  The Board also approved the change in compensation to Bernard Cohen to $65,000 cash per annum and $10,000 per annum payable in the Company's unregistered, voting common stock. The cash compensation is to be paid on the normal payroll cycle of 15th and 31st of each month and stock compensation to be paid quarterly.  Shares are to be priced at the average of all trading day closing quotes on the OTC-BB for the month preceding date of issuance, with such shares to be issued on the first business day after the close of each calendar quarter or as soon thereafter as practicable.  The first such issuance to occur on April 3, 2017. As of the filing date, the shares have not been issued. As of March 31, 2017, the Company has recognized $21,250 as stock compensation, which is included on the Company's Balance Sheet in Accounts Payable and Accrued Expenses.

8

ITEM 2.Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion should be read in conjunction with our financial statements and the notes thereto which appear elsewhere in this report.  The results shown herein are not necessarily indicative of the results to be expected in any future periods.

Forward-Looking Statements: Certain statements made throughout this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance, achievements, costs or expenses and may contain words such as "believe," "anticipate," "expect," "estimate," "project," "budget," or words or phrases of similar meaning.  Forward-looking statements involve risks and uncertainties which may cause actual results to differ materially from those projected in the forward-looking statements.  Such risks and uncertainties are detailed from time to time in reports filed by the Company with the Securities and Exchange Commission, including Forms 8-K, 10-Q and 10-K and include among others the following: promulgation and implementation of regulations by the U.S. Food and Drug Administration ("FDA"); promulgation and implementation of regulations by foreign governmental instrumentalities with functions similar to those of the FDA; costs of research and development and trials, including without limitation, costs of clinical supplies, packaging and inserts, patient recruitment, trial monitoring, trial evaluation and publication; and possible difficulties in enrolling a sufficient number of qualified patients for certain clinical trials.  The Company is also dependent upon a broad range of general economic and financial risks, such as possible increases in the costs of employing and/or retaining qualified personnel and consultants and possible inflation which might affect the Company's ability to remain within its budget forecasts. The principal uncertainties to which the Company is presently subject are its inability to ensure that the results of trials performed by the Company will be sufficiently favorable to ensure eventual regulatory approval for commercial sales, its inability to accurately budget at this time the possible costs associated with hiring and retaining of additional personnel, uncertainties regarding the terms and timing of one or more commercial partner agreements and its ability to continue as a going concern.

The risks cited here are not exhaustive. Other sections of this report may include additional factors which could adversely impact the Company's business and future operations. Moreover, the Company is engaged in a very competitive and rapidly changing industry.

New risk factors emerge from time to time and it is not possible for management to predict all such risk factors, nor can it assess the impact of all such risk factors on the Company's business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those projected in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual future events.

Overview. ABI has been (and is) engaged in the business of biopharmaceutical research and development. Its primary focus historically has been the development of low-dose, orally administered interferon. ABI holds or licenses various patents; it also is the developer of Maxisal^®, a dietary supplement to treat dry-mouth symptoms.

9

Having successfully reorganized, the Company's goal continues to be the expansion of the reach of its research, development, and marketing of biopharmaceutical, biotechnical, health and life science related products.  ABI will continue to leverage its core technology going forward by using its thirty years of scientific and clinical data to establish interferon-alpha lozenges as a therapeutic agent for conditions such as influenza, hepatitis C, and various causes of thrombocytopenia just to name a few.  The Company is committed to expanding its business operations from the currently narrow focus to encompass a wide variety of licensing, partnerships, and development opportunities in the aforementioned sectors. This commitment extends not only to the U.S., but to Taiwan, China, and other Asian Countries.

ABI holds various patents and related intellectual property, which are described earlier in this document. The most significant asset is intellectual property consisting of four patents, one continuation application on a newly issued patent, and one trademark. One of the patents expires in less than two years and two of the patents expire in a range of three to five years. The newly issued patent will expire in April, 2033.  Additionally, the newly issued patent has an international counter-part in Taiwan which is expected to issue in the next few months.  These four patents, the continuation application and the single, soon-to-be-issued, pending patent in Taiwan, employ the Company's core technology, which is the oral, low dosage use of (human) interferon. These patents will not have significant value unless commercialized, which will require adequate funding, time, effort, and expertise in biologics.  As previously stated, ABI's sole source of human interferon discontinued production, which negatively impacted ABI's ability to obtain source product. The anticipated location and development time required for a new source of human interferon along with the requisite testing and FDA approval time could exceed the life span of all but the newest of the patents, and even if it does not, could leave relatively little time to derive revenues from the patent protections, prior to patent expiration. The patent which also carries the trademark, a product promoting oral health, also is the victim of supply-chain interruption because the supplier of the raw material for the product (anhydrous crystalline maltose, or "ACM") has substantially increased its purchase price. The price increase and other actions have rendered the manufacture and sale of the product less attractive.

It is anticipated that ABI will attempt to monetize and commercialize its existing intellectual property, which would necessitate identification and acquisition of new source product (e.g., Interferon), conducting new trials, and additional protection of intellectual property. It is estimated this may require additional funding (including general administrative cost and professional fees) of between $500,000 and $800,000. Similarly, ABI may explore the acquisition and development of new product lines. The cost to commercialize any such development could likely require a similar funding level, resulting in aggregate funding requirements between $1 million and $1.6 million. These activities, even if undertaken, would not be expected to produce meaningful revenue before the last calendar quarter of 2017, or possibly later.

Results of Operations for Three Months Ended March 31, 2017 and 2016:

Revenues.  During the three months ended March 31, 2017 and 2016, there were no product sales. 

Research and Development Expenses.  Research and development expenses have not been incurred for the three months ended March 31, 2017 and 2016.

10

Selling, General and Administrative Expenses.  Selling, general and administrative expenses of $185,013 were incurred for the three months ended March 31, 2017, compared to $121,279 for the three months ended March 31, 2016, an increase of $63,734 (53%).  This increase is contributed to increased salary expense, $42,525 (140%), vacation expense as associated with the increase in salaries, $12,007 (226%), and depreciation related to the addition of APT equipment in Taiwan of $3,974 (1202%).

Operating Loss.  In the three months ended March 31, 2017, the Company's operating loss was $185,013 compared to an operating loss for the three months ended March 31, 2016 of $121,279, a $63,734 increase. This increase is contributed to the additional salary and benefit expense.

Interest Expense.  During the three months ended March 31, 2017, interest expense was $3,959, compared to $362 for the three months ended March 31, 2016.  The interest expense recognized in the three months ended March 31, 2017 is mostly due to accrued interest for our convertible debt notes with Stephen Chen.

Net Loss. In the three months ended March 31, 2017, the Company's net loss was $188,972 compared to a net loss for the three months ended March 31, 2016, of $121,641, a $67,331 (55%) increase. This increase is contributed to the additional salary and benefit expense.

Liquidity and Capital Resources

At March 31, 2017, we had available cash of $52,971 whereas we had a cash position of $134,125 as of December 31, 2016.  The Company had a working capital deficit of $1,101,617 at the end of March 2017.  As of December 31, 2016, the working capital deficit was $1,010,176.  Historically the burn rate was between $50,000 and $60,000 per month.  It is difficult to estimate the burn rate at this point insomuch as the new business lines and revenue streams are still being developed.  One of the Company's main goals is to return to the status of a going concern by having reduced operating losses and subsequently becoming profitable.  As indicated throughout this document, two other major goals of ABI are to (1) leverage the core technology, low-dose oral interferon, and (2) diversify Company operations to incorporate additional lines of business which will extend the reach of ABI into additional economic sectors such as biotech / bio-pharmaceutical / health care products and life sciences business.  The investor base has indicated the willingness to assist in future financing of operations as ABI seeks to monetize its existing (and potentially newly developed) intellectual property. ABI estimates its post-reorganization financing needs to be between $1,000,000 and $1,600,000.

There can be no assurance that we will be successful in our efforts to make the Company profitable.  If those efforts are not successful, we will be forced to cease operations.

ITEM 3.Quantitative and Qualitative Disclosures About Market Risk.

As a "smaller reporting company", we are not required to provide the information under this Item 3.

11

ITEM 4.Controls and Procedures

Disclosure Controls and Procedures

At the end of the period covered by the Annual Report on Form 10-K for the fiscal year ended  December 31, 2016, and this Form 10Q Quarterly Report for the quarter ending March 31, 2017, an evaluation was carried out under the supervision of and with the participation of our management, including the Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO"), of the effectiveness of the design and operations of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) under the Exchange Act). Based on that evaluation, the CEO and the CFO have concluded that as of the end of the period covered by the Annual Report and Quarterly Report, our disclosure controls and procedures were not effective in ensuring that: (i) information required to be disclosed by us in reports that we file or submit to the SEC under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in applicable rules and forms and (ii) material information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow for accurate and timely decisions regarding required disclosure.

Changes to Internal Controls and Procedures over Financial Reporting

There were no changes in our internal controls over financial reporting that occurred during the quarterly period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Management's Remediation Plans

Our management is responsible for establishing and maintaining adequate internal control over financial reporting to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles ("GAAP"). Management has assessed the effectiveness of internal control over financial reporting based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO") in Internal Control-Integrated Framework. A material weakness, as defined by SEC rules, is a control deficiency, or combination of control deficiencies, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. The material weaknesses in internal control over financial reporting that were identified are:

a) We did not maintain sufficient personnel with an appropriate level of technical accounting knowledge, experience, and training in the application of GAAP commensurate with our complexity and our financial accounting and reporting requirements. We have limited experience in the areas of financial reporting and disclosure controls and procedures. Also, we do not have an independent audit committee. As a result, there is a lack of monitoring of the financial reporting process and there is a reasonable possibility that material misstatements of the financial statements, including disclosures, will not be prevented or detected on a timely basis; and

12

b) Due to our small size, we do not have a proper segregation of duties in certain areas of our financial reporting process. The areas where we have a lack of segregation of duties include cash receipts and disbursements, approval of purchases and approval of accounts payable invoices for payment. This control deficiency, which is pervasive in nature, results in a reasonable possibility that material misstatements of the financial statements will not be prevented or detected on a timely basis.

c) We do not have sufficient controls over authorization and documentation of revenue and equity transactions.

We will look to increase our personnel resources and technical accounting expertise within the accounting function as funds become available. Management believes that hiring additional knowledgeable personnel with technical accounting expertise will remedy the following material weakness: insufficient personnel with an appropriate level of technical accounting knowledge, experience, and training in the application of GAAP commensurate with our complexity and our financial accounting and reporting requirements.

PART II - OTHER INFORMATION

ITEM 1. Legal Proceedings.

From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. As of the date of this report, we were not aware of any such legal proceedings or claims against us.

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds.

On September 30, 2016, the Board of Directors approved the Company to amend the previously authorized Private Placement 2016-2 offer, sale, and issuance of unregistered securities.  The Private Placement 2016-2 was amended to offer up to 10,000,000 shares of the Company's common stock at a price of $.1875 per share for an aggregate offering amount of $1,875,000.  The offering is to be completed within one (1) year of the date of approval.  During the first quarter of 2017, the Company sold 270,000 shares of common stock at $.1875 per share for proceeds of $50,625.

ITEM 3. Defaults Upon Senior Securities.

None

ITEM 4. Mine Safety Disclosures.

Not applicable

ITEM 5. Other Information.

None

ITEM 6. Exhibits.

None

13

SIGNATURES

Pursuant to the requirements of Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	AMARILLO BIOSCIENCES, INC.
Date:   May 12, 2017	By: /s/ Stephen T. Chen  Stephen T. Chen, Chairman of the Board, and Chief Executive Officer
Date:   May 12, 2017	By: /s/ Bernard Cohen   Bernard Cohen, Vice President, Chief Financial Officer

14

EX-31.1A

EXHIBIT 31.1a

FORM OF CERTIFICATION

PURSUANT TO RULE 13a-14 AND 15d-14

UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

CERTIFICATION

I, Stephen T. Chen, certify that:

1.I have reviewed this report on Form 10-Q of Amarillo Biosciences, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the periods covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this  report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize, and report financial information; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:  May 12, 2017	/s/ Stephen T. Chen
	Name:  Stephen T. Chen Title: Chairman and Chief Executive Officer

EX-31.1B

                     EXHIBIT 31.1b

FORM OF CERTIFICATION

PURSUANT TO RULE 13a-14 AND 15d-14

UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

CERTIFICATION

I, Bernard Cohen, certify that

1.I have reviewed this report on Form 10-Q of Amarillo Biosciences, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the periods covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize, and report financial information; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:  May 12, 2017	/s/ Bernard Cohen
	Name:  Bernard Cohen Title: Vice President, Chief Financial Officer

EX-32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Amarillo Biosciences, Inc. on Form 10-Q for the period ended March 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), each of the undersigned, in the capacities and on the dates indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

	AMARILLO BIOSCIENCES, INC.
Date:   May 12, 2017	By: /s/ Stephen T. Chen     Stephen T. Chen, Chairman of the Board, and Chief Executive Officer
Date:   May 12, 2017	By: /s/ Bernard Cohen     Bernard Cohen, Vice President, Chief Financial Officer

XML

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2017	May 12, 2017
Document Information [Line Items]
Entity Registrant Name	AMARILLO BIOSCIENCES INC
Entity Central Index Key	0001014763
Trading Symbol	amar
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		22,350,935
Document Type	10-Q
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q1
Amendment Flag	false

XML

Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Assets
Cash and cash equivalents	$ 52,971	$ 134,125
Inventory		14,700
Advance to related party	37,835	37,835
Prepaid expense and other current assets	61,463	75,739
Total current assets	152,269	262,399
Patents, net	155,962	156,063
Property and equipment, net	39,910	44,214
Total assets	348,141	462,676
Liabilities and Stockholders' Deficit
Accounts payable and accrued expenses	142,918	165,502
Accrued interest - related parties	7,154	3,259
Advance from related party	187,500	187,500
Customer deposits – related parties	124,833	124,833
Convertible note payable – related party	791,481	791,481
Total current liabilities	1,253,886	1,272,575
Total liabilities	1,253,886	1,272,575
Commitments and contingencies
Stockholders' deficit
Preferred stock, $0.01 par value: Authorized shares - 10,000,000, Issued and outstanding shares – 0 at December 31, 2016 and December 31, 2015
Common stock, $0.01 par value: Authorized shares - 100,000,000, Issued and outstanding shares – 22,350,935 and 21,916,143 at March 31, 2017 and December 31, 2016, respectively	223,509	219,161
Additional paid-in capital	326,318	237,540
Accumulated deficit	(1,455,572)	(1,266,600)
Total stockholders' deficit	(905,745)	(809,899)
Total liabilities and stockholders’ deficit	$ 348,141	$ 462,676

XML

Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2017	Dec. 31, 2016
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares authorized (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	22,350,935	21,916,143
Common stock, shares outstanding (in shares)	22,350,935	21,916,143

XML

Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenues:
Product sales
Total revenues
Cost of revenues:
Product costs
Total cost of revenues
Gross margin
Operating expenses:
Selling, general and administrative expenses	185,013	121,279
Total operating expenses	185,013	121,279
Operating loss	(185,013)	(121,279)
Other income (expense):
Interest expense	(3,959)	(362)
Net loss	$ (188,972)	$ (121,641)
Basic and diluted net loss per average share available to common shareholders (in dollars per share)	$ (0.01)	$ (0.01)
Weighted average common shares outstanding – basic and diluted (in shares)	22,277,261	20,144,810

XML

Condensed Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Net cash provided by (used in) operating activities:	$ (126,512)	$ 1,663
Cash flows from investing activities:
Investment in patents	(5,267)	(8,617)
Net cash used in investing activities	(5,267)	(8,617)
Cash flows from financing activities:
Proceeds from private placement offering	50,625	250,000
Net cash provided by financing activities	50,625	250,000
Net change in cash	(81,154)	243,046
Cash and cash equivalents at beginning of period	134,125	21,138
Cash and cash equivalents at end of period	52,971	264,184
Supplemental disclosure of cash flow information:
Cash paid for interest
Cash paid for income taxes
Noncash transactions:
Conversion of accounts payable – related party to convertible note payable – related party		$ 144,426

XML

Note 1 - Organization and Business

3 Months Ended

Mar. 31, 2017

Notes to Financial Statements

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

1.

Organization and Business. Amarillo Biosciences, Inc. (the "Company” or “ABI”), a Texas corporation formed in 1984, is engaged in developing biologics for the treatment of human and animal diseases. The Company’s current focus is research aimed at the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon alpha that is administered in a proprietary low dose oral form. In addition to the above core technology, which is included in the Pharmaceutical Division, ABI is exploring the possibility of instituting new revenue streams with a Medical Division and a Consumer Products Division.

The Medical Division is preparing to deploy diabetic treatment centers in Taiwan beginning sometime in the third quarter of 2017. These centers will provide a therapy (Artificial Pancreas Treatment, or "APT") for the management of Type 1 and Type 2 diabetes along with the reversal of the complications that historically accompany this disease and plague patients. The Consumer Product Division is presently working on a delivery system for nutraceuticals and food supplements such as Vitamin C, negotiations to import and distribute to the Asian markets a natural resource product which can be modified for human, animal, or agricultural applications, and enter the alternative medicine market through domestic and international distribution of natural Kentucky Wild Ginseng and other medicinal herbs.

XML

Note 2 - Basis of Presentation

3 Months Ended

Mar. 31, 2017

Notes to Financial Statements

Basis of Accounting [Text Block]

2. Basis of presentation. The accompanying financial statements, which should be read in conjunction with the financial statements and footnotes included in the Company's Form 10 -K for the year ended December 31, 2016, filed with the Securities and Exchange Commission, are unaudited, but have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2017 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2017.

XML

Note 3 - Financial Condition

3 Months Ended

Mar. 31, 2017

Notes to Financial Statements

Financial Condition [Text Block]

3.

Financial Condition. These financial statements have been prepared in accordance with United States generally accepted accounting principles, on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has not yet achieved operating income, and its operations are funded primarily from debt and equity financings. However, losses are anticipated in the ongoing development of its business and there can be no assurance that the Company will be able to achieve or maintain profitability.

The continuing operations of the Company and the recoverability of the carrying value of assets is dependent upon the ability of the Company to obtain necessary financing to fund its working capital requirements, and upon future profitable operations. The accompanying financial statements do not include any adjustments relative to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result from the outcome of this uncertainty.

There can be no assurance that capital will be available as necessary to meet the Company's working capital requirements or, if the capital is available, that it will be on terms acceptable to the Company. The issuances of additional equity securities by the Company

may

result in dilution in the equity interests of its current stockholders. Obtaining commercial loans, assuming those loans would be available, will increase the Company's liabilities and future cash commitments. If the Company is unable to obtain financing in the amounts and on terms deemed acceptable, the business and future success

may

be adversely affected and the Company

may

cease operations. These factors raise substantial doubt regarding our ability to continue as a going concern.

XML

Note 4 - Common Stock

3 Months Ended

Mar. 31, 2017

Notes to Financial Statements

Stockholders' Equity Note Disclosure [Text Block]

4.	Common Stock. The shareholders have authorized 100,000,000 shares of voting common shares for issuance. On March 31, 2017, a total of 26,661,574 shares of common stock were either issued (22,080,935) or reserved for issuance to an investor (270,000) or conversion of convertible debt to stock (4,310,639).
	On March 10, 2016, the Board of Directors approved the Company to enter into private placements for the sale of up to 5,000,000 shares of the Company’s common stock (Private Placement 2016 - 2) at a price of $.1875 per share (aggregate offering amount of $937,500).
	On September 30, 2016, the Board of Directors approved the Company to amend the previously authorized Private Placement 2016 - 2 offer, sale, and issuance of unregistered securities. The Private Placement 2016 - 2 was amended to offer up to 10,000,000 shares of the Company’s common stock at a price of $.1875 per share for an aggregate offering amount of $1,875,000. The offering is to be completed within one (1) year of the date of approval. During the first quarter of 2017, the Company sold 270,000 shares of common stock at $.1875 per share for proceeds of $50,625.
	On January 3, 2017, Stephen T. Chen, CEO, and Bernard Cohen, CFO/VP, received 145,405 shares of common stock and 19,387 shares of common stock, respectively, as payment of a 2016 stock bonus totaling $42,500. The stock was issued at a price of $.2579 per share pursuant to the Board of Directors resolution of December 20, 2016.
	No stock has been sold subsequent to the balance sheet date of March 31, 2017 and through the issue date of this report.

XML

Note 5 - Convertible Notes Payable - Related Party

3 Months Ended

Mar. 31, 2017

Notes to Financial Statements

Convertible Debt [Text Block]

5.

Convertible Notes Payable – Related Party. During the fiscal year ended December 31, 2016, a payable in the amount of $144,426 to Dr. Stephen T. Chen, Chairman, CEO and President of the Company, was exchanged for a convertible promissory note. The note was executed on January 11, 2016, is payable on demand, and is unsecured. The interest rate is .75%, the Annual Federal Rate (AFR), the rate in effect when the note was made. The Payee, Dr. Chen, may convert all or some part of the note to the Maker’s (ABI’s) common voting stock at a conversion price of $.168 per share.

On March 18, 2016, Dr. Chen purchased a Convertible Promissory Note in the amount of $262,500 through the Company’s Private Placement Convertible Note Security Offering entitled Private Placement 2016 - 1 (previously approved by the ABI Board of Directors on March 10, 2016). The note is payable on demand, unsecured, carries interest at the Short Term Annual Federal Rate (AFR) of .65% per annum, and is convertible into ABI common stock at a price of $.1875 per share.

On

June

30,

2016,

a Convertible Promissory Note in the amount of

$384,555

was issued to Dr. Chen in exchange for the aggregated amounts of

two

existing Notes Payable – Related Party. The Convertible Note is due on demand, is unsecured, bears interest at the Short-Term Applicable Federal Rate of

.64%

per annum, and is convertible into ABI common stock at a stock price of

$.1875

per share.

	March 31, 2017		December 31, 2016
Convertible Note payable – related party	$	144,426	$	144,426
Convertible Note payable – related party		262,500		262,500
Convertible Note payable – related party		384,555		384,555
Convertible Notes payable – related party	$	791,481	$	791,481

XML

Note 6 - Related Party Transactions

3 Months Ended

Mar. 31, 2017

Notes to Financial Statements

Related Party Transactions Disclosure [Text Block]

6.	Related Party Transactions. On May 23, 2016, Amarillo Biosciences, Inc. (“ABI”), the Principal, entered into an Agency and Service Agreement with ACTS Global Healthcare, Inc. (“ACTS Global”), a Taiwan Corporation, the Agent. To date, ABI has advanced to ACTS Global “Principal Funds” in the amount of NTD $3,000,681 ($91,968 USD), to be utilized and /or expended by ACTS Global solely as instructed by ABI. Additional advances may be made by ABI to ACTS Global. ACTS Global was also engaged by ABI to perform such other business services as may be requested by ABI in the agreed geographic area of Taiwan and the People’s Republic of China. That Agency Agreement is still in force. For their services, ACTS Global, is be paid by ABI, one percent (1%) of the Principal’s services expended by the Agent at the Principal’s direction. Any other services rendered by the Agent will be paid for by the Principal based on comparable and/or reasonable values of the service rendered. As of March 31, 2017, ACTS Global has a balance of $37,835 to be utilized for the benefit of the Company, which is included on the Company’s Balance Sheet in Advance to related party.
	In April 2016, the Company received proceeds of $187,500 from an investor related to Amarillo Biosciences (Hong Kong) Ltd. in exchange for the potential issuance of 1,000,000 shares of common stock (Private Placement 2016 - 2). As of March 31, 2017, the shares have not been issued and the amount received is included in Advances from related party. As of the filing date, the stock subscription has not been executed.
	On December 20, 2016, effective January 1, 2017, the Board of Directors approved a resolution whereby Dr. Chen's annual compensation was changed to $90,000 cash per annum and $75,000 per annum payable in the Company's unregistered, voting common stock. The Board also approved the change in compensation to Bernard Cohen to $65,000 cash per annum and $10,000 per annum payable in the Company's unregistered, voting common stock. The cash compensation is to be paid on the normal payroll cycle of 15th and 31st of each month and stock compensation to be paid quarterly. Shares are to be priced at the average of all trading day closing quotes on the OTC-BB for the month preceding date of issuance, with such shares to be issued on the first business day after the close of each calendar quarter or as soon thereafter as practicable. The first such issuance to occur on April 3, 2017. As of the filing date, the shares have not been issued. As of March 31, 2017, the Company has recognized $21,250 as stock compensation, which is included on the Company’s Balance Sheet in Accounts Payable and Accrued Expenses.

XML

Note 5 - Convertible Notes Payable - Related Party (Tables)

3 Months Ended

Mar. 31, 2017

Notes Tables

Schedule of Convertible Notes Payable, Related Parties [Table Text Block]

	March 31, 2017		December 31, 2016
Convertible Note payable – related party	$	144,426	$	144,426
Convertible Note payable – related party		262,500		262,500
Convertible Note payable – related party		384,555		384,555
Convertible Notes payable – related party	$	791,481	$	791,481

XML

Note 4 - Common Stock (Details Textual) - USD ($)			1 Months Ended	3 Months Ended		9 Months Ended
	Jan. 03, 2017	Mar. 10, 2016	May 12, 2017	Mar. 31, 2017	Mar. 31, 2016	Sep. 30, 2016	Dec. 31, 2016
Common stock, shares authorized (in shares)				100,000,000			100,000,000
Common Stock, Shares Outstanding and Reserved				26,661,574
Common Stock, Shares, Issued				22,350,935			21,916,143
Common Stock, Shares Subscribed but Unissued				270,000
Amount of Private Placement		$ 937,500				$ 1,875,000
Proceeds from Issuance of Private Placement				$ 50,625	$ 250,000
Subsequent Event [Member]
Shares Authorized During Period, Private Placement			0
Chief Executive Officer [Member]
Deferred Compensation Arrangement with Individual, Shares Issued	145,405
Chief Financial Officer [Member]
Deferred Compensation Arrangement with Individual, Shares Issued	19,387
The Chief Executive Officer and Chief Financial Officer [Member]
Shares Issued, Price Per Share	$ 0.2579
Deferred Compensation Arrangement with Individual, Fair Value of Shares Issued	$ 42,500
Private Placement [Member]
Sale of Stock, Price Per Share		$ 0.1875
Share Price						$ 0.1875
Stock Issued During Period, Shares, New Issues				270,000
Shares Issued, Price Per Share				$ 0.1875
Maximum [Member]
Shares Authorized During Period, Private Placement		5,000,000				10,000,000
Debt Convertible to Common Stock [Member]
Common Stock, Capital Shares Reserved for Future Issuance				4,310,639

XML

Note 5 - Convertible Notes Payable - Related Party (Details Textual) - USD ($)	Mar. 31, 2017	Dec. 31, 2016	Jun. 30, 2016	Mar. 18, 2016
Notes Payable, Convertible, Related Parties, Classified Current	$ 791,481	$ 791,481
Chief Executive Officer [Member] | First Issuance [Member]
Notes Payable, Convertible, Related Parties, Classified Current	144,426	$ 144,426
Debt Instrument, Interest Rate, Stated Percentage		0.75%
Debt Instrument, Convertible, Conversion Price		$ 0.168
Chief Executive Officer [Member] | Second Issuance [Member] | Private Placement Convertible Promissory Notes [Member]
Notes Payable, Convertible, Related Parties, Classified Current	262,500	$ 262,500		$ 262,500
Debt Instrument, Interest Rate, Stated Percentage				0.65%
Debt Instrument, Convertible, Conversion Price				$ 0.1875
Chief Executive Officer [Member] | Third Issuance [Member]
Notes Payable, Convertible, Related Parties, Classified Current	$ 384,555	$ 384,555	$ 384,555
Debt Instrument, Interest Rate, Stated Percentage			0.64%
Debt Instrument, Convertible, Conversion Price			$ 0.1875

XML

Note 5 - Convertible Notes Payable - Related Party - Convertible Notes Payable (Details) - USD ($)	Mar. 31, 2017	Dec. 31, 2016	Jun. 30, 2016	Mar. 18, 2016
Convertible note payable – related party	$ 791,481	$ 791,481
Chief Executive Officer [Member] | First Issuance [Member]
Convertible note payable – related party	144,426	144,426
Chief Executive Officer [Member] | Second Issuance [Member] | Private Placement Convertible Promissory Notes [Member]
Convertible note payable – related party	262,500	262,500		$ 262,500
Chief Executive Officer [Member] | Third Issuance [Member]
Convertible note payable – related party	$ 384,555	$ 384,555	$ 384,555

XML

Note 6 - Related Party Transactions (Details Textual)				1 Months Ended
	Jan. 01, 2017 USD ($)	May 23, 2016 USD ($)	May 23, 2016 TWD	Apr. 30, 2016 USD ($) shares	Mar. 31, 2017 USD ($)
ACTS Global Healthcare, Inc. [Member]
Payments for Advance to Affiliate		$ 91,968	TWD 3,000,681
Percentage to be Paid to Affiliate for Services Rendered		1.00%	1.00%
Prepaid Expense, Current					$ 37,835
Investor Related to Amarillo Biosciences (Hong Kong) Ltd. [Member] | Proceeds Received In Exchange for Potential Issuance of Common Stock [Member]
Related Party Transaction, Amounts of Transaction				$ 187,500
Investor Related to Amarillo Biosciences (Hong Kong) Ltd. [Member] | Potentially Issuable Common Stock For Cash [Member]
Stock Issuable Upon Receipt of Private Placement Memorandum | shares				1,000,000
Chief Executive Officer [Member]
Allocated Share-based Compensation Expense	$ 75,000
Chief Executive Officer [Member] | Cash Bonus [Member]
Officers' Compensation	90,000
Chief Financial Officer [Member]
Allocated Share-based Compensation Expense	10,000
Chief Financial Officer [Member] | Cash Bonus [Member]
Officers' Compensation	$ 65,000
The Chief Executive Officer and Chief Financial Officer [Member] | Accounts Payable and Accrued Liabilities [Member]
Accrued Employee Benefits, Current					$ 21,250